Literature DB >> 6867069

Vasopressin potentiation in the performance of a learned appetitive task: reversal by a pressor antagonist analog of vasopressin.

A Ettenberg, M Le Moal, G F Koob, F E Bloom.   

Abstract

Rats were tested in a simple one-trial water-finding task for the effects of arginine vasopressin (AVP) on performance of an appetitive task. On the training day, each animal was exposed for 5 min to a novel open-field environment that contained a water-tube located in an alcove set into one of the walls of the enclosure. Immediately upon removal from the enclosure, the animals received a subcutaneous injection of either AVP (1 microgram/rat) or vehicle solution. When water-deprived and tested 48 hr later, vasopressin-treated rats found the water tube reliably faster than controls. In other groups of animals, this potentiation in learned performance was prevented by concurrently treating the rats with a vasopressin analog having potent pressor antagonist properties. These results are consistent with the notion that vasopressin may play a role in memory consolidation, but peripheral visceral factors may mediate this action.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6867069     DOI: 10.1016/0091-3057(83)90294-0

Source DB:  PubMed          Journal:  Pharmacol Biochem Behav        ISSN: 0091-3057            Impact factor:   3.533


  10 in total

1.  Modest neuropsychological deficits caused by reduced noradrenaline metabolism in mice heterozygous for a mutated tyrosine hydroxylase gene.

Authors:  K Kobayashi; Y Noda; N Matsushita; K Nishii; H Sawada; T Nagatsu; D Nakahara; R Fukabori; Y Yasoshima; T Yamamoto; M Miura; M Kano; T Mamiya; Y Miyamoto; T Nabeshima
Journal:  J Neurosci       Date:  2000-03-15       Impact factor: 6.167

2.  Vasopressin has general rate-decreasing effects on schedules maintaining either high or low response rates.

Authors:  F van Haaren; R P Heinsbroek; A Louwerse; N E van de Poll
Journal:  Psychopharmacology (Berl)       Date:  1986       Impact factor: 4.530

3.  Disruption of the ether-a-go-go K+ channel gene BEC1/KCNH3 enhances cognitive function.

Authors:  Akira Miyake; Shinji Takahashi; Yukihiro Nakamura; Kohei Inamura; Shun-Ichiro Matsumoto; Shinobu Mochizuki; Masao Katou
Journal:  J Neurosci       Date:  2009-11-18       Impact factor: 6.167

Review 4.  Pharmacological treatment of PTSD - established and new approaches.

Authors:  Thomas Steckler; Victoria Risbrough
Journal:  Neuropharmacology       Date:  2011-06-29       Impact factor: 5.250

5.  Prion protein is necessary for latent learning and long-term memory retention.

Authors:  N Nishida; S Katamine; K Shigematsu; A Nakatani; N Sakamoto; S Hasegawa; R Nakaoke; R Atarashi; Y Kataoka; T Miyamoto
Journal:  Cell Mol Neurobiol       Date:  1997-10       Impact factor: 5.046

6.  Arginine vasopressin gene expression changes within the nucleus accumbens during environment elicited cocaine-conditioned response in rats.

Authors:  E Rodríguez-Borrero; F Rivera-Escalera; F Candelas; J Montalvo; W J Muñoz-Miranda; J R Walker; C S Maldonado-Vlaar
Journal:  Neuropharmacology       Date:  2009-07-09       Impact factor: 5.250

7.  EEG effects of subcutaneous and intracerebroventricular injections of arginine vasopressin in the rat.

Authors:  C L Ehlers; T K Reed; M Wang; C J Lebrun; G F Koob
Journal:  Psychopharmacology (Berl)       Date:  1985       Impact factor: 4.530

8.  Effect of three different cultivars of Lepidium meyenii (Maca) on learning and depression in ovariectomized mice.

Authors:  Julio Rubio; Maria Caldas; Sonia Dávila; Manuel Gasco; Gustavo F Gonzales
Journal:  BMC Complement Altern Med       Date:  2006-06-23       Impact factor: 3.659

9.  Task-specific enhancement of hippocampus-dependent learning in mice deficient in monoacylglycerol lipase, the major hydrolyzing enzyme of the endocannabinoid 2-arachidonoylglycerol.

Authors:  Yasushi Kishimoto; Barbara Cagniard; Maya Yamazaki; Junko Nakayama; Kenji Sakimura; Yutaka Kirino; Masanobu Kano
Journal:  Front Behav Neurosci       Date:  2015-06-02       Impact factor: 3.558

10.  The KCNH3 inhibitor ASP2905 shows potential in the treatment of attention deficit/hyperactivity disorder.

Authors:  Shinji Takahashi; Makoto Ohmiya; Sokichi Honda; Keni Ni
Journal:  PLoS One       Date:  2018-11-21       Impact factor: 3.240

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.